Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-11-23
DOI
10.1111/cas.13889
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome
- (2017) Tsubasa Miyazaki et al. JOURNAL OF NEURO-ONCOLOGY
- “Paradoxical” findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab
- (2017) Yohei Yamamoto et al. Oncotarget
- Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma
- (2017) Song Xue et al. Oncotarget
- The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis
- (2017) Song Xue et al. Scientific Reports
- Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion
- (2016) Stephanie Du Four et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
- (2016) Melanie Ruf et al. INTERNATIONAL JOURNAL OF CANCER
- The impact of hypoxia on tumor-associated macrophages
- (2016) Anne-Theres Henze et al. JOURNAL OF CLINICAL INVESTIGATION
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
- (2016) Sarah T. Garber et al. NEURO-ONCOLOGY
- Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
- (2016) H. Rexer et al. UROLOGE
- Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
- (2016) H. Rexer et al. UROLOGE
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Histopathological investigation of glioblastomas resected under bevacizumab treatment
- (2016) Ryota Tamura et al. Oncotarget
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma: Table 1.
- (2015) Gordana Vlahovic et al. NEURO-ONCOLOGY
- Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
- (2015) Jiabei He et al. Scientific Reports
- Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment
- (2014) Vinit Kumar et al. IMMUNOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cellular and molecular origin of tumor-associated macrophages
- (2014) R. A. Franklin et al. SCIENCE
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
- (2013) I. B. Barsoum et al. CANCER RESEARCH
- Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
- (2013) C. Lu-Emerson et al. NEURO-ONCOLOGY
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
- Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients
- (2010) Ingrid M.E. Desar et al. INTERNATIONAL JOURNAL OF CANCER
- A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
- (2010) Olivier Adotevi et al. JOURNAL OF IMMUNOTHERAPY
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1α
- (2008) Jeremy Ben-Shoshan et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance
- (2008) Paola Allavena et al. IMMUNOLOGICAL REVIEWS
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors
- (2008) Joannes F.M. Jacobs et al. NEURO-ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started